An Introduction to Oncology
Inflammatory immune cells are involved in tumour development and dissemination. As the tumour develops, cancer cells evolve different mechanisms in order to evade attack, by avoiding the immune recognition and developing an immunosuppressive microenvironment. Harnessing the patient’s immune system to attack the tumour is the key principle of immunotherapy. Several classes of immunotherapies including cytokines, monoclonal antibodies against immune checkpoints, autologous dendritic cells expressing tumour antigen, genetically engineered oncolytic viruses and T-cells engineered to expressed chimeric antigen receptors (CAR-T cells), have been approved for many cancer subtypes, including solid tumours and haematological malignancies. Current challenges include elucidating predictive biomarkers, since many people fail to respond to these therapies.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Pia Kvistborg, ESMO 2020 – The ORF1ab of SARS-CoV-2 Encodes an Immunodominant Epitope Restricted by HLA-A*01:01
touchIMMUNOLOGY meets Dr Pia Kvistborg at the Virtual 2020 ESMO Congress to discuss the presentation of her late-breaking abstract ‘The ORF1ab of SARS-CoV-2 encodes an immunodominant epitope restricted by HLA-A*01:01’ (LBA73) and initial findings from her recent study. Questions How did your collaboration with Andrea Cossarizza on SARS-CoV-2 come about? (0:12) How have you applied cancer […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!